Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Satellos Bioscience Inc Com V.ICO


Primary Symbol: ICOTF

iCo Therapeutics Inc is a Canada based biotechnology company. It is involved in the Research and development of ophthalmic indications. The company identifies, develops, and commercialize drug candidates with clinical history, and re-doses, reformulates and develops these drug candidates to treat sight and life-threatening diseases. Its in-licensed assets are iCo-008 and the Oral AmpB Delivery System. iCo-008 is a human monoclonal antibody targeting eotaxin-1 that acts as a messenger between...


GREY:ICOTF - Post by User

Bullboard Posts
Comment by PivotPointNewsWireon Dec 11, 2012 11:49am
421 Views
Post# 20713130

RE: warrants

RE: warrants

The warrants from the last .45 cent financing have a two year shelf life. The warrants are on a one to one basis which if all the warrants are exercised will generate $3,405,199.00 for the company moving forward. An extra $3.4 million in the bank should be able to carry ICO into 2014 without needing any additional financing.

July 13, 2012, Vancouver, Canada—iCo Therapeutics Inc. (“iCo” or “the Company”) (TSX-V: ICO) announced today that it has closed its previously announced prospectus offering of 5,675,332 units (“Units”) at a price of $0.45 per Unit for aggregate gross proceeds of $2,553,899.40 (the “Offering”). Each Unit is comprised of one common share of the Company (a “Common Share”) and one common share purchase warrant (a “Warrant”). Each Warrant entitles the holder to acquire one Common Share at a price of $0.60 per share for a period of 2 years following closing of the Offering.

https://www.pivotpointnewswire.com/

Bullboard Posts